YIBAI PHARMACEUTICAL(600594.SH)

Last Updated 00:00:00
longbridge loading

A-share Three Major Indices Fell Collectively, Computing Hardware Active Against the Trend, Hang Seng Tech Index Down Over 1%, AI Large Model Stocks Rebound, KNOWLEDGE ATLAS Rises 7%

Wallstreetcn·
HK
02513
+1.07%
SZ
002793
+2.56%
SZ
002589
-2.30%
Wallstreetcn·
HK
02513
+1.07%
SZ
002793
+2.56%
SZ
002589
-2.30%

China's A-share pharmaceutical industry chain continues to strengthen, with Chimin and CMC hitting the daily limit, following TJPC, YIBAI PHARMACEUTICAL, and PKU HEALTHCARE also hitting the daily limit. Previously, Huaren Health, Baheal Medical, SYPM, INNOSTIC, and HRPC, among other stocks, rose more than 5%

Wallstreetcn·
SZ
301017
+1.84%
SH
600488
-1.50%
SZ
301584
-3.03%
Wallstreetcn·
SZ
301017
+1.84%
SH
600488
-1.50%
SZ
301584
-3.03%

YIBAI PHARMACEUTICAL: Children's cough syrup resumes production and sales

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit

Zhitong·
SZ
301331
-0.64%
SZ
002873
-1.33%
SZ
300158
-1.93%
Zhitong·
SZ
301331
-0.64%
SZ
002873
-1.33%
SZ
300158
-1.93%

YIBAI PHARMACEUTICAL: Loss of 19.9021 million yuan in the first half of the year

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%

A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%

Wallstreetcn·
SZ
300158
-1.93%
SZ
002287
-0.63%
SH
600594
-2.81%
Wallstreetcn·
SZ
300158
-1.93%
SZ
002287
-0.63%
SH
600594
-2.81%

YIBAI PHARMACEUTICAL received the "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%

YIBAI PHARMACEUTICAL: Expected net profit loss of 21.24 million to 17.70 million yuan in the first half of 2025

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%

YIBAI PHARMACEUTICAL released its first-quarter performance, with a net loss attributable to the parent company of 9.3857 million yuan, narrowing the loss

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%

YIBAI PHARMACEUTICAL issues a profit warning, expecting a net loss of 285 million to 342 million yuan for the fiscal year 2024

Zhitong·
SH
600594
-2.81%
Zhitong·
SH
600594
-2.81%
© 2026 Longbridge｜Disclaimer